Endocannabinoid system and mood disorders: Priming a target for new therapies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F13%3A00067765" target="_blank" >RIV/00216224:14740/13:00067765 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0163725812002409" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0163725812002409</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pharmthera.2012.12.002" target="_blank" >10.1016/j.pharmthera.2012.12.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Endocannabinoid system and mood disorders: Priming a target for new therapies

Popis výsledku v původním jazyce

The endocannabinoid system (ECS), comprising two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle delta 9-tetrahydrocannabinol [delta 9-THC]), their endogenous small lipid ligands (namelyanandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and degradation, has been suggested as a pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiopathological conditions. In the brain activation of this system modulates the release of excitatory and inhibitory neurotransmitters and of cytokines from glial cells. As such, the ECS is strongly involved in neuropsychiatric disorders, particularly in affective disturbances such as anxiety and depression.

Název v anglickém jazyce

Endocannabinoid system and mood disorders: Priming a target for new therapies

Popis výsledku anglicky

The endocannabinoid system (ECS), comprising two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle delta 9-tetrahydrocannabinol [delta 9-THC]), their endogenous small lipid ligands (namelyanandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and degradation, has been suggested as a pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiopathological conditions. In the brain activation of this system modulates the release of excitatory and inhibitory neurotransmitters and of cytokines from glial cells. As such, the ECS is strongly involved in neuropsychiatric disorders, particularly in affective disturbances such as anxiety and depression.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacology & Therapeutics

ISSN

0163-7258

e-ISSN

—

Svazek periodika

138

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

20

Strana od-do

18-37

Kód UT WoS článku

000316520600002

EID výsledku v databázi Scopus

—